Cervical cancer vaccine in Pakistan: let\u27s start thinking by Jawaid, Ali
eCommons@AKU
Medical College Documents Medical College, Pakistan
March 2008
Cervical cancer vaccine in Pakistan: let's start
thinking
Ali Jawaid
Aga Khan University
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_mc
Part of the Oncology Commons
Recommended Citation
Jawaid, A. (2008). Cervical cancer vaccine in Pakistan: let's start thinking. International Journal of Infectious Diseases, 12(2), 217-217.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_mc/4
Esra Tanyel*
Nuriye Tasdelen-Fisgin
Hanife Sarikaya-Genc
Levent Doganci
Necla Tulek
Department of Clinical Microbiology and
Infectious Diseases, Medical School,
Ondokuz Mayis University, 55139, Samsun, Turkey
*Corresponding author.
Tel.: +90 362 3121919/3805
E-mail address: estanyel@yahoo.com.tr
(E. Tanyel)
Corresponding Editor: William Cameron, Ottawa, Canada
19 October 2006
doi:10.1016/j.ijid.2007.04.016
Cervical cancer vaccine in Pakistan: let’s start
thinking
Khan et al. have very meticulously demonstrated an almost
synonymous seropositivity of human papilloma virus 16
(HPV16) among cervical cancer patients in Pakistan.1 The
results call for immediate measures to be taken by the health
authorities in the country, and the suggested connotation
regarding a regular HPV screening of Pakistani women is
verily justified. However, I believe that the implications of
this finding should not be limited to a regular general popula-
tion HPV screening only.
Cervical cancer remains one of the most common malig-
nancies among women around the globe and is the second
leading cause of cancer-related death among women.2
Strong religious and cultural constraints have so far pre-
vented a cervical cancer epidemic in Pakistan, with the
incidence in the female population much lower than breast
and ovarian cancers.3,4 However, with the loosening of cul-
tural boundaries, this may not hold true in a couple of
decades time. Lately, it has been suggested that HPV may
have a causal association with anal, vulvar, and oropharyn-
geal cancers as well.5
Khan and co-workers’ elucidated finding that HPV serotype
16 is responsible for almost all cases of cervical cancer in
Pakistan, implies a lot more than just general population HPV
screening. Two commercial vaccines that cover HPV16 manu-
factured by Merck and GlaxoSmithKline have undergone suc-
cessful advanced clinical trials in the USA.2,6 Moreover, it has
been shown that vaccination against certain viral proteins of
HPV16 induces ananti-viral response thatneutralizes across all
known strains of HPV.7 Owing to the success of the vaccines,
the American Cancer Society now recommends a routine HPV
vaccination for females aged 11—12 years.8 An overwhelming
seropositivity of HPV16 among cervical cancer patients in
Pakistan indicates that preventing the infection of HPV16 by
applying the vaccination strategy could substantially reduce
the incidence of the malignancy in this country.
It is true that the cost—utility of the suggested wide-
population HPV vaccination is yet to be gauged. It does,
however, stand out as a strategy that health authorities in
Pakistan and other developing countries should seriously
consider in the near future, if not now.
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